; on behalf of the SEGURTB study group from GETECCU [LTBI] is affected by steroid and/or immunosuppressant therapy. The aim of this study was to compare performance of the two-step TST in inflammatory bowel disease patients immediately before anti-tumour necrosis factor [TNF] therapy as part of routine screening for LTBI vs control patients when the TST was carried out at an early stage. Methods: In this multicentre prospective controlled study, we evaluated the performance of twostep TST with 5-mm threshold. Factors associated with TST results were determined by logistic regression. 
Introduction
Active tuberculosis [TB] will develop in 5% to 15% of persons with latent infection during their lifetimes, and this proportion is higher in the case of immunocompromised individuals. 1 Tumour necrosis factor [TNF] antagonists are highly effective treatments for many immune-mediated inflammatory diseases [IMID] , including Crohn´s disease and ulcerative colitis. However, whereas TNF is a central cytokine in the pathogenesis of inflammatory bowel diseases [IBD] , it is also a critical component of host defence against Mycobacterium tuberculosis. Therefore, use of TNF antagonist is associated with an increased risk of active TB. 2 When TB develops in patients on anti-TNF therapy, it is more commonly atypical, often occurring at extrapulmonary sites and sometimes progressing to disseminated disease with a potentially fatal outcome. 2, 3 Screening and treating latent TB infection [LTBI] before use of anti-TNF therapy has decreased the risk of active TB. 4 Therefore, preventive treatment should be offered to all patients with evidence of LTBI before starting any anti-TNF agent. [3] [4] [5] [6] In Spain, which has a low to intermediate incidence of TB, recommended TB screening before the use of anti-TNF therapy includes a careful history [including epidemiological risk factors], a two-step tuberculin skin test [TST] , and a chest radiograph. 7 In rheumatic patients receiving anti-TNF agents, the incidence of active TB decreased by 78% after the adoption of official recommendations. 4 Unfortunately, despite all preventive actions, new cases of active TB still occur in patients on anti-TNF therapy.
In patients with IMID there is a pronounced negative effect of steroid and/or immunosuppressant therapy on the rate of positive TST results. [8] [9] [10] Therefore, to maximise TST sensitivity, early screening with TST for LTBI has been suggested, ideally at diagnosis or in absence of any steroid or immunosuppressant therapy, but this strategy has never been evaluated.
The aim of the study was to evaluate the results of the two-step TST in IBD patients. We compared the performance of the two-step TST in two groups of patients: those selected for initial anti-TNF therapy in whom the TST was part of the mandatory routine screening for LTBI, vs control patients in whom the TST was carried out at an early stage before prescribing anti-TNF therapy.
Materials and Methods

Study design
This was a multicentre prospective controlled study. The study was approved by the local ethical committees of all centres. Informed consent was obtained from each participant.
Patients
The anti-TNF group included consecutive IBD patients with an indication for initial treatment with anti-TNF agents, in whom the routine screening for TB was mandatory. The control group included IBD patients for whom anti-TNF therapy was not planned in the short term. Inclusion criteria applicable to all patients were age ≥ 18 years and diagnosis of IBD according to the recommendations of the European Crohn's and Colitis Organisation [ECCO] . 11, 12 The exclusion criteria were previous positive TST, present or past active TB, previous anti-TNF therapy, and pregnancy.
Demographic and clinical information was recorded in a key encrypted electronic case report form designed specifically for the study. IBD patients were classified according to the Montreal classification. 13 All patients were asked about previous screening for LTBI and history and symptoms of active TB. We also sought information on accepted risk factors for LTBI such as close contact with patients with active TB [past or in last year], stays in a TB-endemic area [born or staying longer than 3 months in countries with a high TB prevalence according to the World Health Organization classification], and smoking habits. Bacillus Calmette-Guérin [BCG] vaccination status was recorded according to vaccination history or by evidence of a characteristic skin scar. The dose and duration of immunosuppressants [azathioprine, mercaptopurine,e and methotrexate], systemic steroids, beclometasone dipropionate, budesonide, and 5-aminosalicylates [mesalazine or sulphasalazine] were recorded before LTBI screening. We defined immunosuppressant therapy as use of immunosuppressants for at least 2 months. Steroid therapy was defined as use of systemic steroids at any dose for at least 2 weeks. C-reactive protein [CRP] value was collected at baseline and classified by the number of times above the upper limit of normal. We also recorded relevant comorbidities. 
Screening for LTBI
Results
In total, 615 patients from 33 hospitals were considered for inclusion. Seven patients were excluded due to previous positive TST, and two due to previous exposure to TNF antagonists. A further 26 patients were excluded due to lack of compliance in the performance of the two-step TST: in three patients the first TST was not administered, and in 23 patients the retest was not performed despite induration < 5 mm in the first test. 
Univariate analysis of factors associated with TST results
In the univariate analysis [ Table 2 ], positive TST was associated with higher age, BCG vaccination, ulcerative colitis vs Crohn´s disease, and 5-aminosalicylate therapy. A negative TST was associated with anti-TNF group vs control group, elevated CRP, and steroids and/or immunosuppressant therapy.
Multivariate analysis of factors associated with TST results
Factors showing significant association in the univariate analysis were retained in the logistic model [ Figure 1 ]. The association between steroid and/or immunosuppressant therapy with negative TST remained for both groups without significant differences. 
Impact of CRP on TST results among patients without steroids and/or immunosuppressant therapy
Discussion
Improvement in the accuracy of tests for the diagnosis of LTBI is crucial in countries such as Spain where, despite preventive action, new cases of active TB still occur in IMID patients on anti-TNF therapy.
In our study, which included 243 IBD patients selected for anti-TNF therapy and 337 IBD control patients, we found that the sensitivity of TST is severely affected if the test is performed immediately before the initiation of TNF therapy, as mandated by Spanish recommendations for LTBI screening. Our data indicate that performing the TST at an early stage [before scheduling anti-TNF therapy and in the absence of steroids and/or immunosuppressant therapy] increases the likelihood of detecting LTBI in IBD patients.
A unified consensus statement regarding preventive actions before starting therapy with TNF antagonists is not available. Guidelines for screening for LTBI in patients on anti-TNF therapy differ significantly between countries because they take into account local TB rates and other factors. In Spain, with a relative high risk of active TB in IMID patients under anti-TNF therapy, 14 a preventive strategy [which included careful history, a two-step TST, and a chest radiograph] was associated with a 78% decrease in active TB in rheumatic patients receiving TNF antagonists. 4, 15 However, new cases of active TB still occur in anti-TNF treated IBD patients despite compliance with recommended preventive measures. 16, 17 One difficulty in evaluating performance of LTBI screening methods is the lack of a gold standard for defining LTBI. Ultimately, the aim is to prevent progression to active TB, but this event is too infrequent in IBD patients following current preventive recommendations to be useful as an endpoint in studies of performance of LTBI screening. The only way to assess the specificity of test is therefore to assess association of positive results with classic risk factors of LTBI. 18 In our patients, positive TST was independently associated with higher age, which supports the robustness of our results. We also found that male patients or patients with risk factors for LTBI showed a trend towards a higher rate of positive TST. BCG vaccination correlated with positive TST in univariate analysis, but this effect depended on age in the multivariate analysis. The age of the BCG-vaccinated population was significantly higher than the age of the unvaccinated population. The difference in age completely explained the higher rate of positive TST in the BCG-exposed population. BCG exposure did not modify the effect of age and steroid and/or IMM treatments on the TST results. Therefore BCG vaccination did not influence TST results in our study. This is to be expected, given that BCG was administered during the first year of life and that the interval between vaccination and TST was longer than 15 years in all patients. 19, 20 Lack of accuracy of LTBI screening methods could be associated with incident cases of active TB after a negative screening. In the high-risk setting resulting from the use of immunosuppressive therapies in a population with high rates of LTBI, implementation of strategies to increase sensitivity of LTBI screening would seem appropriate. To maximise TST sensitivity, we used a two-step TST with 5-mm threshold. In our study, LTBI was detected by a 'booster' TST retest in 25% of patients, which is a higher rate than in a previous study in IBD patients in Spain [14%]. 21 Importantly, rheumatologists in Spain found that new cases of active TB occur due to lack of compliance with screening recommendations, with an inadequate two-step TST procedure being a major pitfall. 15 Therefore in Spain, a positive result in the two-step TST is a strong indication for prophylaxis in patients scheduled for anti-TNF therapy, regardless of BCG vaccination history.
Current therapies for IMID include immunosuppressive medications that may affect T cell function, resulting in anergy to TST and other skin tests. 5 Unfortunately, individuals for whom the TST has limited sensitivity are often the patients at increased risk of progression to active TB if infected. Therefore, minimising the influence of factors known to adversely affect TST is a critical factor in the performance of the test for LTBI. 22 In the present study, we clearly demonstrate that results from TST are severely affected by steroids or immunosuppressant therapy, leading to a lower rate of positive TST. Of note, patients treated with both steroids and immunosuppressant therapy had an 80% reduction in the rate of positive TST. Previous studies assessing the effect of immunosuppressants on TST results in IBD patients have been contradictory, reporting either that TST results are negatively affected 23 or not affected by immunosuppressant therapy. [24] [25] [26] Conversely, the negative influence of steroids on TST performance has been demonstrated in several studies. 6, 27, 28 In our study, the likelihood of a positive TST was almost double in the control group ['early TST', regardless of duration of disease] than in the anti-TNF group ['routine TST']. This difference is partially explained by the greater proportion of anti-TNF group patients who were receiving immunosuppressants. Although immunosuppressant therapy equally affects the performance of the TST in both cohorts, 63% of anti-TNF group patients vs 35% of controls were on immunosuppressants at the time the TST was performed [p < 0.001].The problem is that in clinical practice, IBD patient candidates for anti-TNF therapy are too severely ill to stop steroids and/or immunosuppressants before anti-TNF therapy is started. On the other hand, in the subpopulation without steroid or immunosuppressant therapy, the likelihood of positive TST was also more than twice in control patients that in anti-TNF group patients. This difference is partly explained by anti-TNF group patients having almost double the proportion of elevated CRP levels compared with control patients. Among patients without steroid or immunosuppressant therapy, those with elevated CRP had a non-significant 32% reduction in the likelihood of positive TST. None of the 26 patients with a CRP level > 10 times the upper normal level had a positive TST. Significant depression of delayed-type hypersensitivity response to skin antigens has been associated with systemic inflammation measured by erythrocyte sedimentation rate in patients with rheumatoid arthritis. 29 To our knowledge this study is the first to link CRP with decreased response to TST. Therefore, to maximise sensitivity, TST should preferably be performed in the absence of immunosuppressive treatment and/or significant systemic inflammation. The sensitivity of TST is highest in patients who meet the above criteria and who are treated with 5-aminosalicylates, and this occurs more frequently in the control patients. Among patients with no steroid and/or immunosuppressant therapy and with a normal CRP, the likelihood of positive TST [adjusted by age] was also significantly higher in control patients. Therefore lower age, immunosuppressive therapy, or inflammatory activity do not completely explain the lower rate of positive TST in the anti-TNF group. In previous studies, scarcely known factors inherent to IMID by itself, or with associated malnutrition, negatively affected TST performance. 26, 30, 31 It has been suggested that screening for LTBI in IMID patients should be performed early, preferably before initiation of any steroid or immunosuppressant therapy, 9, 24 but this strategy has never been evaluated. To our knowledge, our study is the first to demonstrate that performing TST before scheduling anti-TNF therapy increased sensitivity in the detection of LTBI in IBD patients. We should expect a high rate of false-negative results if we perform the 'routine TST' just before initiation of TNF antagonists, because at that time the vast majority of patients are inevitably receiving immunosuppressive drugs and/or have a high inflammatory activity. By contrast, 'early TST' can be performed either at diagnosis before starting immunosuppressive therapy, or at any time in the disease after steroids have been completely tapered.
In our study we have not included an interferon-γ release assay [IGRA] since, when the study was designed, it was not part of Spanish recommendations for screening LTBI before starting anti-TNF therapy. 4, 15, 21 IGRAs could not replace two-step TST since no study has demonstrated benefit of LTBI treatment based on IGRApositive results in our setting, and therefore it would be unethical to withhold prophylaxis in TST-positive and IGRA-negative patients. 15, 25, 32 In addition, the sensitivity of IGRAs also seems to be significantly affected by immunosuppressive therapy, 9, 10, 24, 25 and a study evaluating the performance of 'early IGRA' would be desirable. Given the low sensitivity of both TST and IGRAs, new diagnostic strategies need to be evaluated. 33 Several studies have shown that diagnostic performance for LTBI in IMID improves if an IGRA is used in addition to TST. 10, [34] [35] [36] Therefore, in patients with TB risk factors such as immunosuppressant use and increased risk of progression from infection to disease, a dual strategy based on both TST and IGRA would seem to improve diagnostic yield and should be recommended. 18, 22, 32 Indeed, two recent guidelines recommended that a dual strategy of TST and IGRA should be pursued in our setting. 37, 38 Recommendations in Spain for screening LTBI in patients before anti-TNF therapy may not necessarily apply to countries with lower incidence of TB.
Our study was not designed to guide the approach to a positive TST. TST is designed to identify an adaptive immune response against, but not necessarily a latent infection with, M. tuberculosis. Therefore a majority of individuals with positive TST results had no viable TB bacilli and would not progress to active disease. 39 Considering also that TB preventive treatment is not free of adverse effects, therapy should be restricted to patients who are known to be at higher risk of developing TB. 40 Thus in our setting, all patients scheduled for anti-TNF therapy who had a positive TST should receive preventive therapy, regardless of BCG vaccination history. Conversely, since only a minority of control group patients will need anti-TNF therapy during their lives, there is a risk of overtreating a majority of this population. Furthermore, giving prophylaxis after a positive 'early TST' protects against LBTI reactivation but not against TB contacts in the interval between screening and initiation of anti-TNF therapy. Therefore, in case of a positive 'early TST', it seems advisable to delay preventive therapy until the patient requires biological treatment. All patients with a negative 'early TST' who finally need anti-TNF therapy should be completely rescreened before initiation of treatment.
Our study had other limitations. The lack of a gold standard for LTBI diagnosis makes it impossible to know the actual accuracy of two-step TST. On the other hand, we have not recorded body mass index, albumin, or pre-albumin values, and therefore cannot assess the influence of nutritional status on TST results. Finally, assessment of inflammatory activity based solely on CRP levels is weak, and the study is not powered to detect differences based on CRP in the subpopulation of patients without immunosuppressive treatment.
In conclusion, steroid and/or immunosuppressant therapy had a pronounced negative effect on the rate of positive two-step TST in IBD patients. Since most patients scheduled for anti-TNF therapy are already receiving steroids and/or immunosuppressants, we should expect a high rate of false-negative results if we perform the 'routine TST' just before initiation of TNF antagonists. 'Early TST', performed before planning anti-TNF therapy, allows us to screen patients in the absence of immunosuppressive treatment and/or significant inflammatory activity and thus maximize the sensitivity of TST for detecting LTBI in IBD patients. 'Booster' TST retesting increases sensitivity for detecting LTBI by 20%.
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